Donanemab
Donanemab (USAN; development code LY3002813) is an experimental drug being developed by Eli Lilly for the treatment of Alzheimer's disease.[1] It is a monoclonal antibody designed to target beta-amyloid proteins in the brain which are believed to cause the neurodegeneration seen in Alzheimer's disease.[1] As of January 2021, the drug is in phase II clinical trials where it has shown promise.[2] The drug slowed cognitive decline by 32% in patients with early symptoms of Alzheimer’s disease, over the course of 76 weeks when compared to those who received a placebo.[3][4]
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Target | Beta-amyloid |
| Clinical data | |
| Other names | LY3002813 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6452H10038N1708O2013S42 |
| Molar mass | 145087.70 |
See also
- Aducanumab, a similar monoclonal amyloid beta antibody treatment for Alzheimer's developed by Biogen.
References
- "Donanemab (LY3002813)". Alzheimer's News Today.
- Gina Kolata (January 11, 2021). "Alzheimer's Drug Shows Promise in Small Trial". New York Times.
- Mintun MA, Lo AC, Evans CD, Wessels AM, Ardayfio PA, Andersen SW, et al. (March 13, 2021). "Donanemab in Early Alzheimer's Disease". New England Journal of Medicine.
- Sofia Moutinho (January 11, 2021). "Experimental drug may slow cognitive decline in early Alzheimer's". Science.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.